Hyderabad: Can there is more heartening news than this. Yes, the scientists of Hyderabad-based Bharat Biotech could achieve yet another accomplishment, ahead of all other competitors within India as well globally develop the ‘booster’ – Covaxin (BRV152) which apparently good enough to fight all future variants, including the Omicron, which is engulfing the many countries world over, thick and fast.
Bharat Biotech, not only become a global leader in vaccine innovation and developer of vaccines for infectious diseases, but also made the country proud to succeed in the government’s effort to make India “Athmanirbhar” today. The pharma company has announced results from a study that it conducted at Emory University, demonstrating that sera from subjects who received a booster dose of Covaxin® (BBV152) six months after getting a primary two-dose series of Covaxin® (BBV152), neutralized the SARS-CoV-2 Omicron and Delta variants.
In fact, earlier studies demonstrated the neutralizing potential of Covaxin® (BBV152) against SARS-CoV-2 Variants of Concern Alpha, Beta, Delta, Zeta and Kappa.
The study now will be published on the pre-print server, medRXiv, shortly.
Sera samples from individuals who received a booster of Covaxin® (BBV152) were observed to be effective in neutralizing Omicron and Delta variants on a live virus neutralization assay. The neutralization activity of Covaxin®-boosted sera was comparable to what has been observed in mRNA vaccine-boosted sera against the Omicron variant.
More than 90% of all individuals boosted with Covaxin® (BBV152) showed neutralizing antibodies. All participants received an initial twodose schedule of Covaxin® (BBV152) at Day 0 and Day 28.
“As the dominant Covid-19 variant throughout the world, Omicron poses a serious public health concern,” said Dr Mehul Suthar, an Assistant Professor, Emory Vaccine Center and who led the laboratory analysis.
“Data from this preliminary analysis show individuals receiving a booster dose of Covaxin® have a significant immune response to both the Omicron and Delta variants. These findings suggest that a booster dose has the potential to reduce disease severity and hospitalizations.” Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech said,
“We are in a continuous state of innovation and product development for Covaxin®. The positive neutralization responses against the Omicron and Delta variants, validates our hypothesis of a multi-epitope vaccine generating both humoral and cell mediated immune responses. Our goals of developing a global vaccine against Covid-19 have been achieved with the use of Covaxin® as a universal vaccine for adults and children,” he pointed out.
“The global impact of Omicron shows us that the fight against Covid-19 continues, and we’re encouraged that these data demonstrate the value of Covaxin® as a primary and booster vaccine,” said Dr. Shankar Musunuri, Chairman, CEO and Co-Founder, Ocugen, Inc.
He further said; “These results show how a broad-spectrum vaccine has the potential ability to address ever-shifting public health challenges such as new variants and mutations.” Covaxin® is formulated uniquely such that the same dosage can be administered to adults and children alike. Covaxin® is a ready-to-use, liquid vaccine, stored at 2 – 8°C, with 12 months shelf life and multi-dose vial policy.
The same doses of vaccine can also be used for two-dose primary immunization in adults and children and for booster dose vaccinations, making it truly a universal vaccine.